Joel Neal, MD, PhD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    AstraZeneca
    Topic:
    advisory/consulting
    Date added:
    06/13/2023
    Date updated:
    03/14/2024
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Genentech/Roche
    Topic:
    advisory/consulting, research funding
    Date added:
    06/13/2023
    Date updated:
    03/14/2024
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Exelixis
    Topic:
    advisory/consulting, research funding
    Date added:
    06/13/2023
    Date updated:
    03/14/2024
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Takeda Pharmaceuticals
    Topic:
    advisory/consulting, research funding
    Date added:
    06/13/2023
    Date updated:
    03/14/2024
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Eli Lilly and Company
    Topic:
    advisory/consulting
    Date added:
    06/13/2023
    Date updated:
    03/14/2024
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Amgen
    Topic:
    advisory/consulting
    Date added:
    06/13/2023
    Date updated:
    03/14/2024
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Iovance Biotherapeutics
    Topic:
    advisory/consulting
    Date added:
    06/13/2023
    Date updated:
    03/14/2024
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Blueprint Pharmaceuticals
    Topic:
    advisory/consulting
    Date added:
    06/13/2023
    Date updated:
    03/14/2024
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Regeneron Pharmaceuticals
    Topic:
    advisory/consulting
    Date added:
    06/13/2023
    Date updated:
    03/14/2024
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Natera
    Topic:
    advisory/consulting
    Date added:
    06/13/2023
    Date updated:
    03/14/2024

Pages

Return to 2024 Napa Valley Lung Cancer Conference